Apple needs to pay an extra $184 million in Apple Watch patent infringement case

The roots of this protracted courtroom saga trace back to a pivotal legal milestone reached in November of last year. During that trial, a federal jury determined that Apple had unlawfully utilized and incorporated Masimo’s proprietary patents without authorization. Specifically, the patent infringement revolved around the innovative optical heart-rate monitoring features that have become a cornerstone of the health and fitness tracking capabilities boasted by the Apple Watch. Following that initial jury decision finding Apple liable for infringing upon the specialized technology, Masimo was awarded a substantial $634 million in damages to compensate for the unauthorized use of its intellectual property.

However, the legal process did not conclude with the announcement of the jury’s verdict. In the months that followed, both legal teams engaged in further dispute over secondary financial obligations, particularly concerning whether Apple should be mandated to pay interest on the multi-million-dollar award. The recent ruling by United States District Judge James Selna officially resolved one of these major financial disputes, rejecting a core argument put forward by Apple’s defense counsel.

During the proceedings leading up to this latest decision, Apple’s legal representatives strongly argued against the imposition of additional interest. The company contended that tacking on millions of dollars in interest payments would amount to an unfair and excessive financial windfall for Masimo, far exceeding any actual economic harm suffered by the medical technology firm as a result of the patent infringement.

Judge Selna, however, firmly dismissed Apple’s windfall argument. In his written opinion, the judge relied heavily on established United States Supreme Court guidance, noting that applying interest from the precise time that the royalty payments would have originally been received does not constitute a windfall. Instead, the court emphasized that such interest merely serves the legal purpose of making the patent owner whole, bridging the financial gap caused by the delayed compensation for the unauthorized use of their intellectual property.

While Judge Selna ruled against Apple’s primary objection, the court also tempered the financial outcome by turning down a request made by Masimo’s legal team. Masimo had formally asked the court to apply a significantly higher 7% interest rate to the damages award. Had the judge granted Masimo’s request for the 7% rate, it would have resulted in an even steeper interest payment from Apple totaling approximately $243 million.

Instead of adopting Masimo’s proposed figure, the court opted for a more moderate and legally conservative approach. The presiding judge decided to utilize Masimo’s own corporate borrowing rate, structured to be compounded annually, running continuously from the exact date when the patent infringement officially began. This specific calculation method ultimately yielded the $184 million interest figure that Apple is now legally mandated to pay.

When combined with the initial jury verdict, this latest judicial ruling drastically alters the total financial liability facing the Cupertino-based technology conglomerate. What began as a substantial $634 million bill for Apple following last November’s trial has now ballooned into a staggering $818 million total bill once the newly added interest is factored into the equation.

For a corporate titan like Apple, which regularly commands hundreds of billions of dollars in annual revenue and maintains massive cash reserves, an $818 million penalty is largely considered manageable or even negligible in the grand scheme of its corporate finances. Industry analysts and financial commentators have frequently characterized such sums as relatively minor expenses for a company of Apple’s immense market capitalization. Nevertheless, the resolution of this interest dispute represents a major legal and financial victory for Masimo, a specialized healthcare technology company that has aggressively defended its intellectual property portfolio against larger corporate competitors.